Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways

Abstract

Aim: Aberrant microRNA expression is a common event in cancer drug resistance, however its involvement in malignant pleural mesothelioma (MPM) drug resistance is largely unexplored. We aimed to investigate the contribution of microRNAs to the resistance to drugs commonly used in the treatment of MPM.

Methods: Drug resistant MPM cell lines were generated by treatment with cisplatin, gemcitabine or vinorelbine. Expression of microRNAs was quantified using RT-qPCR. Apoptosis and drug sensitivity assays were carried out following transfection with microRNA mimics or BCL2 siRNAs combined with drugs.

Results: Expression of miR-15a, miR-16 and miR-34a was downregulated in MPM cells with acquired drug resistance. Transfection with miR-15a or miR-16 mimics reversed the resistance to cisplatin, gemcitabine or vinorelbine, whereas miR-34a reversed cisplatin and vinorelbine resistance only. Similarly, in parental cell lines, miR-15a or miR-16 mimics sensitised cells to all drugs, whereas miR-34a increased response to cisplatin and vinorelbine. Increased microRNA expression increased drug-induced apoptosis and caused BCL2 mRNA and protein reduction. RNAi-mediated knockdown of BCL2 partly recapitulated the increase in drug sensitivity in cisplatin and vinorelbine treated cells.

Conclusion: Drug-resistant MPM cell lines exhibited reduced expression of tumour suppressor microRNAs. Increasing tumour suppressor of microRNA expression sensitised both drug resistant and parental cell lines to chemotherapeutic agents, in part through targeting of BCL2. Taken together, these data suggest that miR-15a, miR-16 and miR-34a are involved in the acquired and intrinsic drug resistance phenotype of MPM cells.

Keywords

Malignant pleural mesothelioma / miR-15a / miR-16 / miR-34a / BCL2 / apoptosis

References

[1] Kao SC,Lee K,Clarke S.Malignant mesothelioma..Int Med J2010;40:742-50

[2] Hudson AL,Moon E,Klebe S.Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma..Sci Rep2014;4:6152 PMCID:PMC4139953

[3] Behnam-Motlagh P,Tyler A,Karlsson T.Cisplatin resistance in malignant pleural mesothelioma.2012;INTECH Open Access Publisher

[4] Moody HL,Maher SG.MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma..Mol Ther Nucleic Acids2017;8:317-29 PMCID:PMC5537169

[5] Zauderer MG,Woo K,Ginsberg MS.Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma..Lung Cancer2014;84:271-4 PMCID:PMC4343315

[6] Scherpereel A,Baas P,Clayson H.Guidelines of the european respiratory society and the european society of thoracic surgeons for the management of malignant pleural mesothelioma..Eur Respir J2010;35:479-95

[7] Scherpereel A,Albelda SM.Novel therapies for malignant pleural mesothelioma..Lancet Oncol2018;19:e161-72

[8] Williams M,Blenkiron C.Exploring mechanisms of MicroRNA downregulation in cancer..Microma2017;6:2-16

[9] Reid G.MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets..J Thorac Dis2015;7:1031-40 PMCID:PMC4466421

[10] Xia L,Du R,Zhao L.miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells..Int J Cancer2008;123:372-9

[11] Blower PE,Lin S,Chung JH.MicroRNA expression profiles for the NCI-60 cancer cell panel..Mol Cancer Ther2007;6:1483-91

[12] Reid G,Kirschner MB,Mugridge N.Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma..Ann Oncol2013;24:3128-35

[13] Duan Z,Shen J,Cote G.miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo..Mol Oncol2017;11:151-66 PMCID:PMC5300234

[14] Tang X,Cao P,Huang C.MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression..Oncotarget2016;7:23668-83 PMCID:PMC5029655

[15] El Bezawy R,Pennati M,Gandellini P.Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism..J Hematol Oncol2017;10:19 PMCID:PMC5242015

[16] Misso G,De Rosa G,Lombardi A.Mir-34: a new weapon against cancer?.Mol Ther Nucleic Acids2014;3:e194 PMCID:PMC4222652

[17] Akao Y,Iio A,Takagi T.Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells..Cancer Lett2011;300:197-204

[18] Vinall RL,Wang S,deVere White RW.MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status..Int J Cancer2012;130:2526-38 PMCID:PMC4568996

[19] Zhou Y,Tseng KF,Lu ZG.Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression..Acta Pharmacol Sin2016;37:519 PMCID:PMC4820798

[20] Santoni-Rugiu E,Grauslund M.MicroRNAs as potential biomarkers in malignant pleural mesothelioma..Current Biomarker Findings2015;

[21] Williams M,Cheng YY,Weiss J.miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma..Oncotarget2015;6:23480-95 PMCID:PMC4695131

[22] Livak KJ.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method..Methods2001;25:402-8

[23] Reid G,Patel R,Saxon-Aliifaalogo F.Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase..J RNAi Gene Silencing2009;5:321-30 PMCID:PMC2737234

[24] Kao SC,Williams M,Madore J.Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma..J Thorac Oncol2017;12:1421-33

[25] Kubo T,Tsukuda K,Fukazawa T.Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma..Clin Cancer Res2011;17:4965-74

[26] Zhu W,Wang T,Liu P.miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines..Int J Cancer2010;127:2520-9

[27] Cimmino A,Fabbri M,Ferracin M.miR-15 and miR-16 induce apoptosis by targeting BCL2..Proc Natl Acad Sci U S A2005;102:13944-9 PMCID:PMC1236577

[28] Yang F,Gong ZB,You N.MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment..Technol Cancer Res Treat2014;13:77-86

[29] Cortes-Dericks L,Boesch R,Karoubi G.Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity..BMC Cancer2014;14:304 PMCID:PMC4021184

[30] Magee P,Garofalo M.Role of microRNAs in chemoresistance..Ann Transl Med2015;3:332 PMCID:PMC4690999

[31] Ren L.The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma..Ther Clin Risk Manag2018;14:179-87 PMCID:PMC5790163

[32] Zhao X,Hu J.miR-138 might reverse multidrug resistance of leukemia cells..Leuk Res2010;34:1078-82

[33] Huang N,Qiu W,He J.MiR-15a and miR-16 induce autophagy and enhance chemosensitivity of Camptothecin..Cancer Biol Ther2015;16:941-8 PMCID:PMC4622988

[34] Tsang WP.Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3..Apoptosis2008;13:1215-22

[35] Cittelly DM,Salvo VA,Burow ME.Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors..Carcinogenesis2010;31:2049-57 PMCID:PMC2994280

[36] Lin X,Huang Z,Li H.Downregulation of Bcl-2 expression by miR-34a mediates palmitate-induced Min6 cells apoptosis..J Diabetes Res2014;2014:258695 PMCID:PMC4009326

[37] Kojima K,Nozawa Y,Ito M.MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms..Prostate2010;70:1501-12

[38] An X,Tan T.Regulation of multidrug resistance by microRNAs in anti-cancer therapy..Acta Pharm Sin B2017;7:38-51 PMCID:PMC5237711

[39] Abdi J,Chang H.Role of micro-RNAs in drug resistance of multiple myeloma..Oncotarget2016;7:60723-35 PMCID:PMC5312415

[40] Chakraborty S,Mukherjee S,Adhikary A.Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells..FEBS Lett2014;588:549-59

[41] Chu J,Liu Y,Lv X.E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter..Oncotarget2015;6:31944-57 PMCID:PMC4741652

[42] Liang H,Jiang X,Wang F.miR-16 promotes the apoptosis of human cancer cells by targeting FEAT..BMC Cancer2015;15:448 PMCID:PMC4450989

[43] Li ZH,Xiong QY,Xiao A.miR-34a expression in human breast cancer is associated with drug resistance..Oncotarget2017;8:106270-82 PMCID:PMC5739732

[44] Wen D,Lin F,Mahato RI.Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer..Cancer Res2017;77:3244-54 PMCID:PMC5673080

[45] Siena L,Ferraro M,Melis M.Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing..Immunology2014;141:242-55 PMCID:PMC3904245

[46] Sen S,Singh N.Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway..Biochem Biophys Res Commun2005;331:1245-52

[47] van Zandwijk N,Kao SC,Boyer MJ.Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study..Lancet Oncol2017;18:1386-96